Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$22.17 - $51.8 $115,284 - $269,360
5,200 Added 54.17%
14,800 $765,000
Q2 2022

Aug 08, 2022

SELL
$15.36 - $27.51 $265,728 - $475,923
-17,300 Reduced 64.31%
9,600 $238,000
Q1 2022

May 16, 2022

SELL
$22.22 - $39.12 $193,314 - $340,344
-8,700 Reduced 24.44%
26,900 $674,000
Q4 2021

Feb 14, 2022

BUY
$18.38 - $40.5 $181,962 - $400,950
9,900 Added 38.52%
35,600 $1.3 Million
Q3 2021

Nov 15, 2021

BUY
$13.18 - $19.83 $338,726 - $509,630
25,700 New
25,700 $439,000
Q1 2021

May 17, 2021

SELL
$49.53 - $68.4 $425,958 - $588,240
-8,600 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$47.25 - $65.16 $250,425 - $345,348
5,300 Added 160.61%
8,600 $533,000
Q3 2020

Nov 16, 2020

BUY
$46.35 - $61.69 $152,955 - $203,577
3,300 New
3,300 $181,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.